Adze oncolytic immunotherapies harness immune response mechanisms to enable the patient's body to fight cancers.

Adze oncolytic immunotherapy payloads target immune stimulatory and inhibitory receptors on T, NK, and dendritic cells and macrophages to further amplify the immune response.

The neoantigens released from lysed cancer cells, coupled with recruited and stimulated immune cells, generate in situ systemic cancer vaccine responses, a key goal in immuno-oncology.


Adze Oncolytic Immunotherapies stimulate and recruit innate and adaptive immune responses to cancer.

Adze immunotherapy platforms have several mechanisms of action:

  1. Our systemically deliverable oncolytic viral backbones selectively infect, replicate in, and kill tumor cells:  This releases a full array of neoantigens to a patient's immune system along with immunotherapy payloads generated locally in the tumor as our oncolytic virus replicates. creating an in situ systemic cancer vaccine response.
  2. Our oncolytic immunotherapies induce immunogenic death: releasing markers (such as calreticulin) that activate both the adaptive and innate immune system. The inflamed tumor environment recruits tumor-infiltrating immune cells, turning “cold” tumors “hot”.  The release of neoantigens in the context of immunogenic cell death creates an in situ systemic cancer vaccine response.
  3. Our oncolytic immunotherapies deliver validated immunotherapy payloads at high concentrations into the tumor milieu:  The localized delivery is designed to avoid toxicities normally associated with systemically delivered immunotherapies. 
  4. Our immune stimulatory payload combinations are designed to stimulate a patient's CD8+ T cells, NK cells, dendritic cells and macrophages:  This stimulation results in increased cytokine release, antigen presentation, T cell clonal expansion, and cytoxicity.  
  5. This localized generation of immunotherapies unleashes an extended wave of cancer cell killing by the patient's own immune system.  


Adze oncolytic immunotherapies are designed to be combined with PD-(L)1 therapies

Oncolytic vectors


Genetically Modified Surface Proteins Allow For Systemic And Intra-tumoral Delivery

ADZ Hexon proteins are designed to evade scavenger receptors in the liver's Kupffer cells.  These modifications allow for greater systemic anti-cancer therapy activity.